Navigation Links
Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
Date:11/20/2008

p is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

About Aurigene

Established in Bangalore, India, in 2002, Aurigene Discovery Technologies Ltd., is a drug discovery biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates in oncology, metabolic disorders and autoimmune diseases, with a proven track record of successful partnerships with big and medium-sized pharma and biotech companies globally. Aurigene has 10 drug discovery collaborations and a pipeline of 15 discovery programs at various stages, from Hit Generation to late-stage Pre-Clinical Optimization, and has filed 14 patents across 6 programs over the last 12 months.

With proprietary Structural Biology and Fragment-based Drug Design technology platforms, and experienced scientific leadership, Aurigene is a fully integrated operation with expertise in Hit Generation to Drug Development Candidates for IND nomination.

    Debiopharm S.A. Contacts
    Maurice Wagner
    Director Corporate Affairs & Communications
    Tel.: +41(0)21-321-01-11
    Fax:  +41(0)21-321-01-69
 
'/>"/>
SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
2. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
3. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
4. Debiopharm and EPFL Establish an Oncology Chair
5. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
6. Japanese Cancer Association and Debiopharm Honour Japanese Research
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
10. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
11. Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... -- GenomeDx Biosciences today announced that a new study ... test for prostate cancer, was able to predict rapid ... prostatectomy without adjuvant therapy. Although rapid metastasis in men ... genomics to identify these men who have a highly ... The study has been published online by the ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
Breaking Biology Technology:Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... 28 Clarisonic announced today the expansion of its ... with Look Good…Feel Better ®, ... with breast and other cancers manage their treatment and ... program,s free workshops, volunteer beauty professionals teach patients easy ...
... at the University of New South Wales (UNSW) in Sydney, ... to make a quantum computer using silicon: a "single electron ... Quantum computers promise exponential increases in processing speed over ... orientation, of individual electrons to represent data in their calculations. ...
... day recycle part of their own waste heat, using a ... The material is a semiconductor called gallium manganese arsenide. In ... describe the detection of an effect that converts heat into ... a semiconductor. Once developed, the effect could enable integrated ...
Cached Biology Technology:Clarisonic Empowers Cancer Patients to Put Their Best Face Forward 2Clarisonic Empowers Cancer Patients to Put Their Best Face Forward 3Clarisonic Empowers Cancer Patients to Put Their Best Face Forward 4Clarisonic Empowers Cancer Patients to Put Their Best Face Forward 5Single electron reader opens path for quantum computing 2Semiconductor could turn heat into computing power 2Semiconductor could turn heat into computing power 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... buildings and monuments may be better protected from decay ... Researchers at the University of Edinburgh have devised a ... stone buildings including statues, monuments and other historic ... development allows conservationists to estimate the likely impact of ...
... By creating a unique system of blood vessels that ... implanted device, the longevity and function of these devices ... by researchers in the University of Louisville/ Jewish Hospital,s ... online on August 23, 2010 in the Journal ...
... studies show that treatments targeting specific viral genes protected ... the animals were protected even when therapeutics were administered ... treating accidental infections in laboratory or hospital settings. ... the journal Nature Medicine , was conducted by ...
Cached Biology News:Study offers historic buildings protection from climate change 2New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports 2Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 2Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 3
Lysozyme C (W-20)...
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
... (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a chromogenic ... recombinant plasmids. In the ... IPTG, lac + ... whereas recombinant colonies appear ...
... AcTEV Protease is an enhanced form of ... highly site-specific, highly active, and significantly more ... long-term activity. AcTEV Protease specifically recognizes a ... and Gly), making it useful for removing ...
Biology Products: